Preview

Современная ревматология

Расширенный поиск

Актуальные вопросы применения ингибиторов фактора некроза опухоли α при ревматоидном артрите

https://doi.org/10.14412/1996-7012-2008-507

Полный текст:

Аннотация

Применение ингибиторов фактора некроза опухоли (ФНО) а в комбинации с метотрексатом остается основным методом лечения активного ревматоидного артрита (РА). Это направление в противоревматической терапии стремительно развивается. На повестке дня - ряд нерешенных вопросов, связанных с отбором пациентов (особенно на ранней стадии РА) для лечения антагонистами ФНО а, прогнозированием его эффективности, изучением сравнительных аспектов терапии. Появление в России самого современного ингибитора ФНО а - адалимумаба, обладающего неоспоримыми достоинствами, открывает новые перспективы в лечении РА.

Литература

1. <div><p>Feldmann M., Maini R.N. Discovery of TNF-a as a therapeutic target in rheumatoid arthritis: preclinical and clinical studies. Joint Bone Spine 2002; 69: 12-8.</p><p>Насонов Е.Л. Моноклональные антитела к фактору некроза опухоли в ревматологии. РМЖ 2003; 11: 390-4.</p><p>Choy E.H., Panayi G.S. Cytokine pathways and joint inflammation in rheumatoid arthritis. N Engl J Med 2001; 344: 907-16.</p><p>Насонов Е.Л. Фармакотерапия ревматоидного артрита - современные рекомендации. Врач 2007; 1: 38-42.</p><p>Furst D.E., Breedveld FC., Kalden J.R. et al. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2007. Ann Rheum Dis 2007; 66 (suppl. III): iii2-iii22.</p><p>Лукина Г.В., Сигидин Я.А., Чичасова Н.В. и др. Применение моноклональных антител к фактору некроза опухоли (ремикейд) при ревматоидном артрите: предварительные результаты. Тер арх 2003; 5: 9-12.</p><p>Лукина Г.В., Сигидин Я.А., Позднякова Е.С. и др. Инфликсимаб в терапии ревматоидного артрита. Науч-практич ревматол 2007; 4: 60-5.</p><p>Насонов Е.Л. Перспективы применения полностью человеческих моноклональных антител к фактору некроза опухоли (адалимумаба) при ревматоидном артрите. Клин фармакол терапия 2007; 1: 71-4.</p><p>Alonso-Ruiz A., Pijoan J.I., Ansuategui E. et al. Tumor necrosis factor alpha drugs in rheumatoid arthritis: systematic review and metaanalysis of efficacy and safety. BMC Musculoskelet Disord 2008; 17; 9(1): 52.</p><p>Weinblatt M.E., Keystone E.C.,Furst D.E. et al. Adalimumab, a Fully Human AntiTumor Necrosis Factor-а Monoclonal Antibody, for the Treatment of Rheumatoid Arthritis in Patients Taking Concomitant Methotrexate. The ARMADA Trial. Arthritis Rheum 2003; 48(1): 35-45.</p><p>Burmester G., Mariette X., Montecucco C. et al. Adalimumab alone and in combination with disease-modifying antirheumatic drugs for the treatment of rheumatoid arthritis in clinical practice: the Research in Active Rheumatoid Arthritis (ReAct) trial. Ann Rheum Dis 2007; 66: 732-9.</p><p>Weinblatt M.E., Keystone E.C.,Furst D.E. et al. Long term safety, efficacy and remission with adalimumab (Humira) and methotrexate combination therapy in rheumatoid arthritis (RA) 7-year analysis. Abstr. 9th Annual EULAR 2008 meeting, Paris, AB0343.</p><p>Насонов Е.Л. Почему необходима ранняя диагностика и лечение ревматоидного артрита? РМЖ 2002; 10(22): 1009-11.</p><p>Ikeda K., Cox S., Emery P. Biological therapy in early arthritis - overtreatment or the way to go? Arthritis Research Therapy 2007; 9: 211-8.</p><p>Breedveld F., Weisman M., Kavanaugh A. et al. A Multicenter, Randomized, Double-Blind Clinical Trial of Combination Therapy With Adalimumab Plus Methotrexate Versus Methotrexate Alone or Adalimumab Alone in Patients With Early, Aggressive Rheumatoid Arthritis Who Had Not Had Previous Methotrexate Treatment. Arthritis Rheum 2006; 54: 26-37.</p><p>Keystone E., Kavanaugh A., Sharp J. et al. Radiographic, Clinical, and Functional Outcomes of Treatment With Adalimumab (a Human Anti-Tumor Necrosis Factor Monoclonal Antibody) in Patients With Active Rheumatoid Arthritis Receiving Concomitant Methotrexate Therapy. Arthritis Rheum 2004; 50(5): 1400-11.</p><p>Keystone E.C., Kavanaugh A.F., Sharp J.T. et al. Inhibition of Radiographic Progression in Patients With Long-Standing Rheumatoid Arthritis Treated with Adalimumab Plus Methotrexate for 5 Years. Abstract presented at 8th Annual European League Against Rheumatism (EULAR 2007); June 13-16, 2007; Barcelona, Spain. Abstract THU0168.</p><p>Emery P., Genovese M., Van Vollenhoven R.; Palra K.; Sasso E.: Less progression of joint erosion (JE) and joint space narrowing (JSN) with adali-mumab plus mtx vs. mtx monotherapy at all levels of clinical response: Subanalysis of premier. Ann Rheum Dis, 66/suppl 2 (169) /2007/. Abstract THU0145.</p><p>Hoff M., Kvien T K., Kдlvesten J. et al. Adalimumab therapy reduces hand bone loss in early rheumatoid arthritis: Explorative analyses from the PREMIER study. Ann Rheum Dis published online 18 Sep 2008; doi:10.1136/ard.2008.091264.</p><p>Kimel M., Cifaldi M., Chen N. et al. Adalimumab plus methotrexate improved SF-36 scores and reduced the effect of rheumatoid arthritis (RA) on work activity for patients with early RA. J Rheumatol 2008; 35(2): 206-15.</p><p>Saag K.G., Teng G.G., Patkar N.M. et al. American College of Rheumatology 2008 Recommendations for the Use of Nonbiologic and Biologic Disease-Modifying Antirheumatic Drugs in Rheumatoid Arthritis. Arthritis Rheum (Arthritis Care &amp; Research) 2008; 59(6): 762-84.</p><p>Gartlehner G., Hansen R.A., Jonas B.L. et al. The comparative efficacy and safety of biologics for the treatment of rheumatoid arthritis: a systematic review and metaanalysis. J Rheumatol 2006; 33: 2398-408.</p><p>Donahue K., Gartlehner G., Jonas D. et al. Systematic Review: Comparative Effectiveness and Harms of Disease-Modifying Medications for Rheumatoid Arthritis. Ann Intern Med 2008; 148: 124-34.</p><p>Chen Y.-F., Jobanputra P., Barton P. et al. A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness. Health Technology Assessment 2006; 10: 42.</p><p>Gartehner G., Hansen R.A., Thieda P. et al. Drug Class Review on Targed Immune Modulators. Final Report 2007. &lt;http://www.ohsu.edu/drugeffec-&gt;α tiveness</p><p>Zink A., Strangfeld A., Schneider M. et al. Effectiveness of Tumor Necrosis Factor Inhibitors in Rheumatoid Arthritis in an Observational Cohort Study Comparison of Patients According to Their Eligibility for Major Randomized Clinical Trials. Arthritis Rheum 2006; 54(11): 3399-407.</p><p>Kievit W., Fransen J., Oerlemans A.J.M. et al. The efficacy of anti-TNF in rheumatoid arthritis, a comparison between randomised controlled trials and clinical practice. Ann Rheum Dis 2007; 66: 1473-78.</p><p>Kievit W., Adang EM., Fransen J. et al. The effectiveness and medication costs of three anti-tumour necrosis factor alpha agents in the treatment of rheumatoid arthritis from prospective clinical practice data. Ann Rheum Dis 2008; 67(9): 1229-34.</p><p>Амирджанова В.Н. Шкалы боли и HAQ в оценке пациента с ревматоидным артритом. Науч-практич ревматол 2006; 2: 60-5.</p><p>Maini R.N., Breedveld F.C., Kalden J.R. et al. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor а monoclonal antibody combined with lowdose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum 1998; 41: 1552-63.</p><p>Baert F., Noman M., Vermeire S. et al. Influence of Immunogenicity on the Long-Term Efficacy of Infliximab in Crohn's Disease. N Engl J Med 20</p><p>; 348: 601-8. Van der Laken J., Voskuyl A.E., Roos J.S. et al. Imaging and serum analysis of immune complex formation of radiolablled infliximab and anti-infliximab in responders and non-responders to therapy of rheumatoid arthritis. Ann Rheum Dis 2007; 66: 253-6.</p><p>Anderson P.J. Tumor necrosis factor inhibitors: clinical implications of their immunogenicity profiles. Semin Arthr Rheum 2005; 3 4 (suppl.I): 19-22. Van der Bijl A.E., Breedveld F.C., Antoni C.E. et al. An open-label pilot study of the effectiveness of adalimumab in patients with rheumatoid arthritis and previous infliximab treatment: relationship to reasons for failure and anti-infliximab antibody status. Clin Rheumatol 2008; 27 (8): 1021-8.</p><p>Finckh A., Ciurea A., Brulhart L. et al. B Cell Depletion May Be More Effective Than Switching to an Alternative Anti-Tumor Necrosis Factor Agent in Rheumatoid Arthritis Patients With Inadequate Response to Anti-Tumor Necrosis Factor Agents. Arthritis Rheum 2007; 56(5): 1417-23.</p><p>Gomez-Reino J., Carmona L. and the BIOBADASER Group. Switching TNF antagonists in patients with chronic arthritis: an observational study of 488 patients over a four-year period. Arthritis Research Therapy 2006; 8: 29.</p><p>Hyrich K., Lunt M., Watson K. et al. Outcomes After Switching From One Anti-Tumor Necrosis Factor-а Agent to a Second Anti-Tumor Necrosis Factor-а Agent in Patients With Rheumatoid Arthritis. Arthritis Rheum 2007; 56(1): 13-20.</p><p>Hjardem E., Østergaard M., Pødenphant J. et al. Do rheumatoid arthritis patients in clinical practice benefit from switching from infliximab to a second tumor necrosis factor alpha inhibitor? Ann Rheum Dis 2007; 66: 1184-9.</p><p>Hyrich K., Lunt M., Dixon W. et al. Effects of switching between anti-TNF therapies on HAQ response in patients who do not respond to their first anti-TNF drug. Rheumatology 2008; 47: 1000-5.</p><p>&lt;http://www.nice.org.uk/nicemedia/pdf/&gt;TNFInhibitorsSequentialFADAmended.pdf</p><p>&lt;http://www.rheumatology.org.uk/media/&gt;pressreleases/lancetarticlemay08</p><p>&lt;http://www.arc.org.uk/news/&gt;pressreleases/nice/untitled.asp</p></div><br />


Для цитирования:


Лучихина Е.Л., Каратеев Д.Е., Luchikhina Y.L., Karateyev D.E. Актуальные вопросы применения ингибиторов фактора некроза опухоли α при ревматоидном артрите. Современная ревматология. 2008;2(4):46-51. https://doi.org/10.14412/1996-7012-2008-507

For citation:


Luchikhina E.L., Karateev D.E., Luchikhina Y.L., Karateyev D.E. USE OF TUMOR NECROSIS FACTOR-A INHIBITORS IN RHEUMATOID ARTHRITIS: TOPICAL ASPECTS. Modern Rheumatology Journal. 2008;2(4):46-51. (In Russ.) https://doi.org/10.14412/1996-7012-2008-507

Просмотров: 886


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 1996-7012 (Print)
ISSN 2310-158X (Online)